Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020.
Proteomedix has been acquired by Blue Water Biotech.

Products, services, technology

Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Core competencies

You may also be interested in